Literature DB >> 11380518

Significance of exaggerated natriuresis after angiotensin AT1 receptor blockade or angiotensin- converting enzyme inhibition in obese Zucker rats.

L S Tallam1, B S Jandhyala.   

Abstract

1. Obese Zucker rats (OZR) were shown to be salt-sensitive in that they develop hypertension when placed on a high-salt diet. Because angiotensin (Ang) II is a major antinatriuretic factor, the present studies were undertaken to determine whether the characteristic of salt-sensitivity of OZR is associated with an enhanced antinatriuretic function of endogenous AngII. 2. The extent of AngII-mediated antinatriuresis was investigated in OZR and lean Zucker rats (LZR) using candesartan (100 microg/kg, i.v.), a selective angiotensin AT1 receptor antagonist, and ramipril (1 mg/kg, i.v.), an angiotensin-converting enzyme (ACE) inhibitor. The total number of AngII binding sites and their affinity were also assessed in renal cortical tubular membrane preparations of OZR and LZR using a specific radioligand-binding assay. Plasma renin activity was determined using a standard radioimmunoassay. 3. Both candesartan and ramipril produced substantially greater increases in urinary sodium excretion and urine flow in OZR and these effects were significantly greater than those observed in LZR. These observations suggest that basal antinatriuretic function of endogenous AngII is exaggerated in OZR. 4. The functional overexpression of AngII was not due to any alterations in the affinity or the total number of AngII binding sites in renal cortical tubular membranes. Higher plasma renin values in the OZR could have contributed to the phenomenon. 5. In conclusion, marked diuresis and natriuresis after AT1 receptor blockade and/or ACE inhibition suggest that the extent of endogenous AngII-mediated sodium transport under basal conditions is greatly augmented in OZR. It is proposed this phenomenon may be a contributing factor for the salt- sensitivity in the OZR.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380518     DOI: 10.1046/j.1440-1681.2001.03457.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  8 in total

1.  High Na intake increases renal angiotensin II levels and reduces expression of the ACE2-AT(2)R-MasR axis in obese Zucker rats.

Authors:  Preethi Samuel; Quaisar Ali; Rifat Sabuhi; Yonnie Wu; Tahir Hussain
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-16

2.  Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats.

Authors:  Isha Dhande; Quaisar Ali; Tahir Hussain
Journal:  Hypertension       Date:  2013-04-01       Impact factor: 10.190

3.  AT2 receptor non-peptide agonist C21 promotes natriuresis in obese Zucker rats.

Authors:  Quaisar Ali; Tahir Hussain
Journal:  Hypertens Res       Date:  2012-02-02       Impact factor: 3.872

4.  Dahl salt-sensitive rats are protected against vascular defects related to diet-induced obesity.

Authors:  Andreas M Beyer; Gabor Raffai; Brian Weinberg; Katherine Fredrich; Julian H Lombard
Journal:  Hypertension       Date:  2012-06-18       Impact factor: 10.190

5.  Inhibition of NAD(P)H oxidase potentiates AT2 receptor agonist-induced natriuresis in Sprague-Dawley rats.

Authors:  Rifat Sabuhi; Mohammad Asghar; Tahir Hussain
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-28

6.  Protective role of angiotensin II subtype 2 receptor in blood pressure increase in obese Zucker rats.

Authors:  Athar H Siddiqui; Quaisar Ali; Tahir Hussain
Journal:  Hypertension       Date:  2008-12-29       Impact factor: 10.190

7.  Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats.

Authors:  Quaisar Ali; Yonnie Wu; Tahir Hussain
Journal:  Kidney Int       Date:  2013-07-03       Impact factor: 10.612

Review 8.  Increased Hydration Can Be Associated with Weight Loss.

Authors:  Simon N Thornton
Journal:  Front Nutr       Date:  2016-06-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.